Recently, Regeneron ( REGN -1.41%) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its previous market value. You might remember that the genetic testing company filed for Chapter 11 bankruptcy protections in March.

Regeneron will acquire 23andMe’s core assets for $256 million, ensuring customer data privacy and continuing the mission of accessible, genome-based health insights.